How does 0JBU's PS Ratio compare to its peers?

0JBU is expensive based on its Price-To-Sales Ratio (33.8x) compared to the peer average (7.1x).

How does 0JBU's PS Ratio compare vs other companies in the GB Biotechs Industry?

0JBU is expensive based on its Price-To-Sales Ratio (33.8x) compared to the European Biotechs industry average (8.1x).

What is 0JBU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JBU is expensive based on its Price-To-Sales Ratio (33.8x) compared to the estimated Fair Price-To-Sales Ratio (0x).

What is the Fair Price of 0JBU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 0JBU's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Intellia Therapeutics (LSE:0JBU) - Stock Price, News & Analysis

0JBU Stock Overview

A genome editing company, focuses on the development of curative therapeutics. More details

0JBU fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 67.24% per year

Risk Analysis

Volatile share price over the past 3 months compared to the UK market

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Intellia Therapeutics, Inc. Competitors

Genus

LSE:GNS

UK£1.1b

Oxford Biomedica

LSE:OXB

UK£442.5m

Bioventix

AIM:BVXP

UK£195.7m

Avacta Group

AIM:AVCT

UK£179.3m

Price History & Performance

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share Price	US$14.32
52 Week High	US$34.87
52 Week Low	US$13.00
Beta	1.81
11 Month Change	-10.68%
3 Month Change	-39.28%
1 Year Change	-53.92%
33 Year Change	-87.72%
5 Year Change	-8.57%
Change since IPO	-42.06%

Recent updates

Shareholder Returns

	0JBU	GB Biotechs	GB Market
7D	-0.2%	0.3%	2.2%
1Y	-53.9%	-18.3%	8.0%

Return vs Industry: 0JBU underperformed the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0JBU underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0JBU's price volatile compared to industry and market?
0JBU volatility
0JBU Average Weekly Movement	10.2%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0JBU's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JBU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2014	526	John Leonard	www.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.

Intellia Therapeutics, Inc. Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
0JBU fundamental statistics
Market cap	US$1.46b
Earnings (TTM)	-US$522.28m
Revenue (TTM)	US$43.09m

33.8x

P/S Ratio

-2.8x

P/E Ratio

Is 0JBU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JBU income statement (TTM)
Revenue	US$43.09m
Cost of Revenue	US$458.42m
Gross Profit	-US$415.33m
Other Expenses	US$106.96m
Earnings	-US$522.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-5.13
Gross Margin	-963.95%
Net Profit Margin	-1,212.19%
Debt/Equity Ratio	0%

How did 0JBU perform over the long term?

See historical performance and comparison

0JBU Stock Overview

Rewards

Risk Analysis

Intellia Therapeutics, Inc. Competitors

LSE:GNS

UK£1.1b

LSE:OXB

UK£442.5m

AIM:BVXP

UK£195.7m

AIM:AVCT

UK£179.3m

Price History & Performance

Recent News & Updates

Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.38 loss in 3Q 2023)

Intellia Therapeutics, Inc. Presents Positive Results from the Phase 2 Study of NTLA-2002

Intellia Therapeutics, Inc. Announces Initiation of Haelo Phase 3 Study of Ntla-2002

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Recent updates

Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.38 loss in 3Q 2023)

Intellia Therapeutics, Inc. Presents Positive Results from the Phase 2 Study of NTLA-2002

Intellia Therapeutics, Inc. Announces Initiation of Haelo Phase 3 Study of Ntla-2002

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Now 25% overvalued

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)